Rationale: Hypoxia-induced pulmonary hypertension involves hypoxia-inducible factor-1␣ (HIF-1␣) activation as well as elevated resting calcium levels. Cyclosporin A (CsA) inhibits calcium-induced calcineurin activation and blocks the stabilization of HIF-1␣ in cultured cells. Objectives: We hypothesized that treatment of rats with CsA would prevent HIF-1-dependent gene transcription, lower specific responses to acute hypoxia, and prevent pulmonary hypertension and right ventricle hypertrophy resulting from prolonged exposure to hypoxia. Methods: Acute and chronic responses to hypoxia were studied in rats treated or not treated with CsA (25 mg · kg
. It is also associated with elevated intracellular calcium resting levels (11) , suggesting the possible involvement of calcium in cellular remodeling.
The transcription factor hypoxia-inducible factor-1 (HIF-1) is a critical regulator of the physiological responses to hypoxia, such as increased glycolysis, angiogenesis, and erythropoiesis (12, 13) . HIF-1 was originally identified as an activator of erythropoietin (EPO) gene expression (14) . HIF-1 plays a pivotal role in the pathogenesis of hypoxia-induced pulmonary hypertension (11, 15) . Partial deficiency of HIF-1␣ delays development of polycythemia, right ventricular hypertrophy, pulmonary hypertension, and hypoxia-induced pulmonary artery smooth muscle cell depolarization and increased calcium levels (11, 15) .
HIF-1 is a heterodimeric transcription factor consisting of a regulated ␣ subunit and a constitutive ␤ subunit (16) . Under normoxic conditions, HIF-1␣ is hydroxylated and acetylated, resulting in its recognition by the von Hippel-Lindau protein, leading to its ubiquitinylation and subsequent degradation through the proteasomal pathway (17) . Hypoxia blocks both HIF-1␣ hydroxylation and acetylation, resulting in its stabilization. Moreover, growth factors or cytokines can induce HIF-1␣ expression in a hypoxia-independent manner (18) . In addition, biochemical factors have been shown to affect HIF-1␣ stabilization. Cyclosporin A (CsA), a well-known inhibitor of the calcium/calmodulin-dependent protein phosphatase calcineurin, can block hypoxia-induced HIF-1␣ accumulation by activating Pro-564 hydroxylation in cultured cells (19) . However, whether repeated CsA administration is able to prevent the transcriptional activity of HIF-1 in vivo, and to modulate the known responses to hypoxia, has not been examined.
Hypoxia-induced pulmonary hypertension leads to increase right ventricular pressure and to right ventricle hypertrophy. Cardiac hypertrophy is a complex process in which calcineurin clearly plays a critical role (20) . Calcineurin is an effective inducer of cardiac growth in response to numerous pathologic stimuli (21) . Inhibition of calcineurin activity with CsA can prevent cardiac hypertrophy in response to various stimuli (22) . Whether enhanced calcineurin activity is involved in the development of pulmonary hypertension and right ventricle hypertrophy in response to chronic hypoxia has not been examined.
Thus, the aim of this experiment was to test the hypothesis that CsA administration in rats would prevent HIF-1-dependent gene transcription, pulmonary hypertension, and right ventricle hypertrophy resulting from chronic exposure to hypoxia.
Some of the results of these studies have been previously reported in the form of abstracts (23) (24) (25) . This article reports our complete study findings.
METHODS
This investigation was performed in accordance with the Helsinki Accords for Humane Treatment of Animals during Experimentation.
Experimental Design
Early responses to hypoxia. Twenty-four rats received intraperitoneally either CsA (Sandimmune, 25 mg · kg
; Novartis, Basel, Switzerland;
T group) or an equivalent dose of sodium chloride solution (U group). Groups were divided into subgroups of n ϭ 6 rats, exposed or not for 6 h to hypoxia in a chamber (Po 2 ϭ 10%). Long-term responses to hypoxia. Forty-three rats were exposed for 3 wk to either hypoxia (H group) or normoxia (N group). Groups were divided in subgroups, in which rats were injected intraperitoneally with either CsA at 25 mg · kg -1 · d -1 (N-CsA and H-CsA, n ϭ 11 and n ϭ 10, respectively), or the equivalent dose of sodium chloride solution (N-C and H-C, n ϭ 11 each). This dose of CsA was chosen according to previous studies using CsA to prevent cardiac hypertrophy in rodents (26, 27) .
Because both hypoxia and CsA treatment decreased the food intake of animals, with an additive effect in the H-CsA group, two additional groups were fed as CsA-treated hypoxic animals maintained in normoxia and treated (PF-CsA) or not treated (PF-C) with CsA, to rule out a possible toxic effect of CsA.
Hemodynamic Measurements
Fourteen animals (5 from the H-CsA group and 3 each from the N-C, N-CsA, and H-C groups) were subjected to hemodynamic measurements after 3 wk of conditioning. Right functional parameters were measured in closed-chest anesthetized rats with a ultraminiature cathe- 
Tissue Processing
All other animals were decapitated at the end of the study. Blood was sampled for hematocrit measurement. The middle lobe of the right lung and kidney cortex were immediately sampled, and frozen in liquid nitrogen. Thereafter, the heart was removed and dissected, with the right ventricle weighed and frozen in liquid nitrogen.
mRNA Analysis
Total RNA was extracted from 5 mg of right ventricle and from 15 mg of kidney and lung, using the RNeasy mini kit procedure (Qiagen, Courtaboeuf, France) in accordance with the company protocol. The RNA concentration was determined by determining optical density at 260 nm. Reverse transcription was performed with a reverse transcription core kit (Eurogentec, Saraing, Belgium) with 2.5 M oligo(dT) 15 primer, according to the manufacturer's instructions.
Oligonucleotide primers used in this study were designed with Mac Vector software (Accelrys, San Diego, CA) and synthesized at Eurogentec (Table 1) . Considering probable disparities due to variations in Definition of abbreviations: CycA ϭ cyclosporin A; EPO ϭ erythropoietin; ET-1 ϭ endothelin-1; Glut-1 ϭ glucose transporter type 1; HPRT ϭ hypoxanthine-guanine phosphoribosyltransferase; 5-HTT ϭ serotonin transporter; LDH-A ϭ lactate dehydrogenase type A; MCIP-1 ϭ modulatory calcineurin-interacting protein-1.
input RNA or in reverse transcription efficiencies, cyclophilin A and hypoxanthine-guanine phosphoribosyltransferase mRNA were also quantified as endogenous housekeeping genes.
Quantitative PCR was performed with a LightCycler FastStart DNA Master SYBR Green I kit with a LightCycler system (Roche Applied Science, Meylan, France). The threshold cycle value was calculated from LightCycler software. Quantification was achieved with a pool of cDNA samples as calibrator according to the comparative threshold cycle method (28) . Accurate normalization was performed by geometric averaging of the two endogenous housekeeping genes (29) . Relative mRNA values were calculated with RealQuant software (Roche Applied Science, Mannheim, Germany).
Statistical Analysis
Data are presented as means Ϯ SEM. CsA treatment and hypoxia effects were determined by two-way analysis of variance. Differences between groups were tested with a Newman-Keuls post hoc test. Statistical significance was accepted at p Ͻ 0.05.
RESULTS

Early Responses to Hypoxia
HIF-1-responsive genes are up-regulated by acute exposure to ambient hypoxia and blunted by CsA treatment in both kidney and lung. In preliminary experiments we examined the induction of hypoxia responsive genes after 2 and 6 h of exposure to hypoxia. Because results obtained after 6 h gave more robust results, a 6-h exposure time was chosen.
EPO was the first hypoxia-sensitive gene described, and is expressed mainly in kidney. CsA treatment lowered EPO mRNA levels in kidney of normoxic rats (p Ͻ 0.001; Figure 1 ). Moreover, EPO mRNA levels were markedly affected by hypoxia (p Ͻ 0.001). In untreated animals EPO mRNA levels were increased after 6 h of hypoxia (p Ͻ 0.001). CsA administration completely abolished the hypoxia-induced increase in EPO mRNA levels (p Ͻ 0.001). An interaction between hypoxia and CsA was observed (p Ͻ 0.001), suggesting that the hypoxia effects differed in untreated and in CsA-treated rats.
Endothelin-1 (ET-1), glucose transporter type 1 (Glut-1), lactate dehydrogenase type A (LDH-A), and 5-HTT are also hypoxia-sensitive genes that are commonly expressed in the lung. In the present study, no global effect of CsA treatment was observed for those genes (Figure 2) . A global effect of Figure 1 . Transcript levels of erythropoietin (EPO) in kidney were measured by real-time polymerase chain reaction, and normalized by geometric averaging of two internal control genes, cyclophilin A and hypoxanthine-guanine phosphoribosyltransferase. EPO mRNA levels was significantly decreased in normoxic cyclosporin A (CsA)-treated rats. The dramatic increase observed in rats subjected to 6 h of hypoxia was completely blocked in hypoxic CsA-treated rats. Results are expressed as a relative percentage of normoxic value. *** Different from normoxic values (p Ͻ 0.001); †, † † † different from untreated animals (p Ͻ 0.05 and p Ͻ 0.001, respectively).
hypoxia was observed for the four hypoxia-sensitive genes ET-1, Glut-1, LDH-A, and 5-HTT (p Ͻ 0.001, p Ͻ 0.01, p Ͻ 0.05, and p Ͻ 0.05, respectively). An interaction between CsA treatment and hypoxia was found, indicating that the acute responses to hypoxia differed between treated and untreated animals. In untreated rats, all mRNA levels were markedly induced by acute hypoxia (p Ͻ 0.001 for ET-1, and p Ͻ 0.05 for Glut-1, 5-HTT, and LDH-A). CsA administration completely abolished the hypoxiainduced expression of HIF-1 target genes. These changes cannot be attributed to a generalized effect of either hypoxia or CsA on gene expression because no significant changes in mRNA levels of the two endogenous housekeeping genes (cyclophilin A and hypoxanthine-guanine phosphoribosyltransferase) used for normalization were observed.
Calcineurin activation is involved in the acute response to hypoxia in the lung. The specific effects of hypoxia and/or CsA administration on calcineurin activity were assessed by measuring mRNA levels of modulatory calcineurin-interacting protein-1 (MCIP-1) in lung (30) . As expected, CsA lowered MCIP-1 mRNA levels in normoxic rats (p Ͻ 0.001). In untreated animals the MCIP-1 mRNA level paralleled the expression of hypoxia-responsive genes ( Figure 3) ; it was increased 2.5-fold 6 h after hypoxia exposure (p Ͻ 0.001), and CsA treatment completely blocked the hypoxia-induced increase in MCIP-1 mRNA expression.
Long-term Responses to Hypoxia
Hematocrit. The increase in red blood cell production is an early general response to chronic hypoxia. Hematocrit was affected both by hypoxia (p Ͻ 0.001) and CsA treatment (p Ͻ 0.001), without interaction (Table 2) . Hypoxia induced an increase in hematocrit both in nontreated rats (p Ͻ 0.001) and in CsA-
Hypoxia-induced right ventricle pressure increase is blunted by CsA treatment. CsA treatment alone did not affect mean right ventricle pressure in normoxic rats (26.5 Ϯ 3.5 vs. 31.3 Ϯ 2.4 mm Hg in normoxia; Figure 4) . A clear consequence of chronic hypoxia is an increased load to the right ventricle. This is evidenced in Figure 4 , where right ventricle pressure increased more than twofold in hypoxic untreated animals (72.7 Ϯ 4.7 mm Hg, p Ͻ 0.001). CsA administration fully prevented the hypoxiainduced increase in right ventricle pressure (22.0 Ϯ 2.3 mm Hg).
CsA treatment reduces the hypoxia-induced absolute and relative increase in right ventricle weight. Both hypoxia (p Ͻ 0.001) and CsA treatment (p Ͻ 0.001) globally affected right ventricle weight, when expressed either as absolute values or relative to body weight (Table 2 ). Hypoxia exposure increased absolute and relative right ventricle weight in nontreated rats (ϩ126 and ϩ152%, respectively; p Ͻ 0.001). CsA treatment strongly reduced the hypoxia-induced increase in absolute and relative right ventricle weight (p Ͻ 0.001). The absolute right ventricle weight was lower in the N-CsA group than in the N-C group (p Ͻ 0.05); however, when expressed relative to body weight, relative right ventricle weight did not differ between these two groups. Whereas absolute right ventricle weight was not different between N-CsA and H-CsA rats, hypoxia induced an increase in relative right ventricle weight in CsA-treated rats (ϩ45%; p Ͻ 0.01). Because CsA and hypoxia induce a decrease in food intake, changes in heart weight were compared also in pair-fed animals. Absolute and relative right ventricle weights were slightly higher in the H-CsA group than in the PF-C group (ϩ21 and ϩ24% for absolute and relative right ventricle weight, respectively) and the PF-CsA group (ϩ27 and ϩ22% for relative right ventricle weight, respectively), which shows that CsA treatment reduces the hypoxia-induced absolute and relative increase in right ventricle weight independently of toxic effects.
Hypoxia increases and CsA blocks calcineurin activation in the right ventricle. We then investigated whether cardiac calcineurin was activated in response to hypoxia and whether CsA was able to block this effect. Both hypoxia (p Ͻ 0.001) and CsA treatment (p Ͻ 0.001) affected MCIP-1 mRNA levels in the right ventricle, with a strong interaction (p Ͻ 0.001) between these two factors ( Figure 5 ). MCIP-1 mRNA levels markedly increased after hypoxia exposure in nontreated rats (ϩ437%; p Ͻ 0.001). This hypoxia-induced increase in MCIP-1 mRNA levels was fully prevented by CsA treatment, so that there was no difference between N-C, N-CsA, and H-CsA groups, showing that calcineurin activation is involved in right ventricle hypertrophy resulting from the hypoxia-mediated pressure overload.
DISCUSSION
The main findings of this study are that, in vivo, (1 ) acute hypoxia increased calcineurin activity in lung, as assessed by MCIP-1 mRNA levels; (2 ) CsA administration abolished the hypoxiainduced increase in calcineurin activity and in the transcription of numerous HIF-1 target genes; (3 ) the hypoxia-induced increase in right ventricle pressure was fully abolished by CsA treatment; and (4 ) the subsequent right ventricle hypertrophy, which was associated with an enhancement in calcineurin activity, was also fully prevented by CsA treatment. Taken together, these results show that CsA prevents hypoxia-induced pulmonary hypertension and its associated right ventricle hypertrophy, either by inhibiting HIF-1 transcriptional activity in lung, decreasing calcineurin activity in lung and heart, by direct effects of CsA, or by a combination of these factors. This is the first evidence that calcineurin activation might be involved in hypoxic signaling leading to pulmonary hypertension.
Acute hypoxia induced the expression of early HIF-1-responsive gene expression. In the present study, calcineurin activity assessed through the level of MCIP-1 gene transcription was dramatically increased in lung after 6 h of acute hypoxia. Administration of CsA, a well-known inhibitor of calcineurin activity (31), led to a 50% decrease in calcineurin activation in the lungs of normoxic CsA-treated animals, and CsA completely abolished the hypoxia-induced increase in MCIP-1 transcription, suggesting that hypoxia activates calcineurin. ET-1 and 5-HT have been shown to play a central role in pulmonary hypertension, acting both as potent pulmonary vasoconstrictors and cellular mitogens on both pulmonary artery smooth muscle cells and adventitial fibroblasts (2), through increased intracellular calcium levels (32, 33) . A link between 5-HT signaling, calcineurin activation, and hypertrophy has been established in cardiac muscle cells (34) . Moreover, in pulmonary arterial smooth muscle cells, acute hypoxia causes depolarization and increased intracellular calcium concentration through storeoperated and voltage-operated calcium channels (35) . Chronic elevation of calcium activates calcineurin, which plays a critical role in smooth muscle cell remodeling through dephosphorylation of nuclear factor-activated T-cell transcription factors (36) . Thus, the hypoxia-induced increase in calcium in pulmonary arterial smooth muscle cells may be responsible for calcineurin activation and MCIP-1 expression in lung after 6 h of acute hypoxia. Interestingly, CsA treatment also inhibited the hypoxiadependent gene transcription of ET-1, Glut-1, and LDH-A in the lung and of EPO in the kidney (12) . Transcript levels of these hypoxia-responsive genes rose markedly, in response to acute hypoxia in untreated animals, and this increase was fully prevented in CsA-treated animals, in parallel with calcineurin activity. It has been previously suggested that 5-HTT could also be an oxygen-sensitive gene (6, 37) . Again, 5-HTT transcription was up-regulated by hypoxia in association with increased calcineurin activity, and this response was also completely blunted by CsA treatment. These results show for the first time that CsA administration in rats prevents the hypoxia-induced transcriptional activation of 5-HTT and of four well-known HIF-1 target genes. However, whether this results from calcineurin activation or from direct effects of CsA remains to be established. Indeed, it has been shown in cultured cells that CsA may interfere with the hypoxic signaling cascade by activating HIF-1␣ hydroxylation, leading to its ubiquitinylation and subsequent degradation, although a possible involvement of calcineurin has not been ruled out in this study (19) . Conversely, because HIF-1␣ subunit can be up-regulated in a hypoxia-independent manner but also in a Ca 2ϩ /calcineurin-dependent manner (38) , it is possible that calcineurin may directly up-regulate HIF-1␣ subunit expression, thus participating in the sustained induction of HIF-1-dependent gene expression. These findings thus suggest that calcineurin may act as a downstream effector of hypoxia in the lung, leading to the proliferation of pulmonary artery smooth muscle cells and adventitial fibroblasts. CsA treatment could prevent pulmonary hypertension both by canceling hypoxia-induced 5-HTT upregulation and inhibiting local ET-1 release, and by inhibiting calcium-dependent calcineurin activation within pulmonary vascular smooth muscle cells and/or adventitial fibroblasts ( Figure 6 ).
Consistent with the prevention of hypoxia-responsive gene activation, CsA treatment was able to prevent some of the specific responses to hypoxia, including erythrocytosis, pulmonary hypertension, and its associated right ventricle hypertrophy. As expected, hematocrit values increased in response to hypoxia and in parallel to increased transcription of the EPO gene in kidney, in a CsA-sensitive manner. Moreover, CsA treatment also prevented both the increase in right ventricular pressure and cardiac hypertrophy usually observed in response to chronic hypoxia (39) . Interestingly, these effects appear similar to those induced by partial deficiency in HIF-1␣ (35) , suggesting a close link between HIF-1␣ and calcineurin.
Calcineurin activation is known to participate in cardiac hypertrophy induced by diverse stimuli (40) . To examine its possible involvement in hypoxia-induced cardiac hypertrophy, we measured the level of MCIP-1 transcript expression. Chronic hypoxia indeed led to increased levels of MCIP-1 mRNA in the right ventricle of untreated animals, an effect that was completely blocked by CsA treatment. The present study suggests for the first time that the calcineurin/nuclear factor-activated T-cell pathway is also involved in hypoxia-mediated right ventricle hypertrophy. However, because CsA blocks pulmonary hypertension, inhibition of hypoxia-induced right ventricle hypertrophy by CsA is due to its antihypertensive rather than antihypertrophic effects.
In conclusion, the present study shows that, in an animal model, CsA administration fully prevented the hypoxia-induced increase in the expression of numerous hypoxia-responsive genes in parallel with changes in calcineurin activity. These early alterations may have long-term consequences on the prevention of hypoxia-induced pulmonary hypertension and its associated right ventricle hypertrophy. Hence, our results suggest a role for calcineurin activity in hypoxia-induced pulmonary hypertension. However, CsA also blocks the adaptive increase in hematocrit in response to chronic hypoxia. Further experiments are needed to define whether calcineurin inhibitors, alone or in conjunction with inhibitors of other signaling pathways (41) (42) (43) , might be useful to prevent and/or reverse hypoxia-induced pulmonary hypertension. Clearly, the present findings have important clinical consequences in providing calcineurin as a new therapeutic target to prevent pulmonary hypertension.
